what types of rapid testing for Covid-19 have been developed?

Covid-19: Testing testing

COVID-19 Follow up Testing

Testing for COVID-19

COVID-19 testing

Rapid review of COVID-19.

Rapid review of COVID-19

Fast Screening Systems for COVID-19

Covid-19: testing times

Fast and simple high-throughput testing of COVID 19

COVID-19 testing.

Covid-19: testing times.

Senegal to trial $1 speedy test for covid-19

Interpreting a covid-19 test result

Interpreting a covid-19 test result.

Evaluation of eleven rapid tests for detection of antibodies against SARS-CoV-2.

Objectives SARS-CoV-2, causing COVID-19, has emerged to cause a human pandemic. Detection of SARS-CoV-2 in respiratory samples by using PCR is the standard laboratory diagnostic tool. Our aim was to perform a limited evaluation of the diagnostic performance and user-friendliness of eleven rapid tests for detection of antibodies against SARS-CoV-2. Methods All participants were tested with PCR against SARS-CoV-2 at a clinical microbiology laboratory. Comparing with results from PCR tests, we evaluated the rapid tests' performances in three arms; 1) 20 hospitalized patients with PCR-confirmed COVID-19, 2) 23 recovered outpatients with former PCR-confirmed COVID-19, and 3) 49 participants with suspected COVID-19 presenting at a primary care emergency room. Results All eleven tests detected antibodies in hospitalized COVID-19 patients, though with varying sensitivities. In former outpatients recovered from COVID-19, there were differences between tests in the immunoglobulin type G (IgG) sensitivity, with five tests having a sensitivity below 65%. In participants with suspected COVID-19 infection, the rapid tests had very low sensitivities. Most rapid tests were easy to perform and interpret. Conclusions Rapid tests were not suited as stand-alone tests to detect present infection in a Norwegian primary care emergency room population. All the rapid tests were able to detect SARS-CoV-2 antibodies, although sensitivities varied and were generally higher in the study arm of more severely affected participants. Rapid tests with high IgG sensitivity (and specificity) may be useful for confirmation of past infection. An independent evaluation should be performed in the intended population before introducing a rapid test.

Covid-19 tests: Collective and individual applications

Covid-19 products

'Test, re-test, re-test': using inaccurate tests to greatly increase the accuracy of COVID-19 testing

Testing for COVID-19 at travel clinics in Japan

COVID-19

Covid-19

COVID-19.

After Covid-19

Covid-19: What is the UK's testing strategy?

Antibody Testing for COVID-19

Commercial influence and covid-19

Covid-19: Why test? Who to test? How to test?

Too slow and fundamentally flawed: why test and trace is a weak and inequitable defence against covid-19.

A COVID-19 Rapid-Response Research Agenda.

COVID 19

COVID-19: TIMING IS IMPORTANT

COVID-19: Timing is Important

Emerging key laboratory tests for patients with COVID-19

Reducing the Risk of Diagnostic Error in the COVID-19 Era.

‘Test, re-test, re-test’: using inaccurate tests to greatly increase the accuracy of COVID-19 testing

The COVID-19 testing debacle

A hidden danger of COVID-19

MinIP technique may be helpful in diagnosing COVID-19.

A hidden danger of COVID-19.

Challenges of Covid-19 testing

No abstract available.

COVID-19 Testing: The Threat of False-Negative Results

Empowering academic labs and scientists to test for COVID-19

COVID-19 current controversies.

A systematic approach is needed to contain COVID-19 globally

The COVID-19 testing debacle.

COVID-19 testing in Africa: lessons learnt

Preparedness and Rapid Implementation of External Quality Assessment Helped Quickly Increase COVID-19 Testing Capacity in the Republic of Korea

High COVID-19 testing rate in Portugal

The positive effects of covid-19.

COVID-19 needs a big science approach

Trends and innovations in biosensors for COVID-19 mass testing.

Fast and widespread diagnosis is crucial to fight against the outbreak of COVID-19. The present work surveys the landscape of available and emerging biosensor technologies for COVID-19 testing. Molecular diagnostic assays based on quantitative Reverse Transcription Polymerase Chain Reaction are used in most clinical laboratories. The COVID-19 pandemic has overwhelmed the testing capacity and motivated the development of fast point-of-care tests and the adoption of isothermal DNA amplification. Antigenic and serological rapid tests based on lateral flow immunoassays suffer from low sensitivity. Advanced digital systems enhance the performance at the expense of speed and large equipment requirement. Emerging technologies, including CRISPR gene-editing tools, benefit from high sensitivity and selectivity of molecular diagnostics and the easy use of lateral flow assays. DNA sequencing and sample pooling strategies are highlighted to bring out the full capacity of the available biosensor technologies and accelerate mass testing.

Distinguishing between direct and indirect consequences of covid-19.

The race against COVID-19

Commercial influence and covid-19.

Controlling COVID-19.

Universal weekly testing as the UK COVID-19 lockdown exit strategy

Can pediatric COVID-19 testing sensitivity be improved with sequential tests?

Can Pediatric COVID-19 Testing Sensitivity Be Improved With Sequential Tests?

Feasibility of controlling COVID-19

The COVID-19 Curriculum

The COVID-19 challenge.

COVID-19 Strikes the Vulnerable

FAST: a Feasible, Accurate and Speedy Test Strategy for COVID-19

As the COVID-19 pandemic continues worldwide, there is an urgent need to detect infected patients as quickly and accurately as possible. Group testing proposed by Technion [2] could improve efficiency greatly. However, the false negative rate (FNR) would be doubled. Using USA as an example, group testing would have over 70,000 false negatives, compared to 35,000 false negatives by individual testing. In this paper, we propose a Flexible, Accurate and Speedy Test (FAST), which is faster and more accurate than any existing tests. FAST first forms small close contact subgroups, e.g. families and friends. It then pools subgroups to form larger groups before RT-PCR test is done. FAST needs a similar number of tests to Technion's method, but could sharply reduce the FNR to a negligible level. Again taking USA as example, FAST reduces the number of false negatives to just 2000 while it is seven times faster than individual testing.

COVID-19 Testing in South Korea: Current Status and the Need for Faster Diagnostics.

Aggregating data from COVID-19 trials

The Challenges Wrought by COVID-19

The Challenges Wrought by COVID-19.

Understanding the Dynamics of COVID-19

Aggregating data from COVID-19 trials.

The race against COVID-19.

The impact of COVID-19

Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection

The current COVID-19 pandemic presents a serious public health crisis, and a better understanding of the scope and spread of the virus would be aided by more widespread testing. Nucleic-acid-based tests currently offer the most sensitive and early detection of COVID-19. However, the "gold standard" test pioneered by the U.S. Centers for Disease Control and Prevention takes several hours to complete and requires extensive human labor, materials such as RNA extraction kits that could become in short supply, and relatively scarce qPCR machines. It is clear that a huge effort needs to be made to scale up current COVID-19 testing by orders of magnitude. There is thus a pressing need to evaluate alternative protocols, reagents, and approaches to allow nucleic-acid testing to continue in the face of these potential shortages. There has been a tremendous explosion in the number of papers written within the first weeks of the pandemic evaluating potential advances, comparable reagents, and alternatives to the "gold-standard" CDC RT-PCR test. Here we present a collection of these recent advances in COVID-19 nucleic acid testing, including both peer-reviewed and preprint articles. Due to the rapid developments during this crisis, we have included as many publications as possible, but many of the cited sources have not yet been peer-reviewed, so we urge researchers to further validate results in their own laboratories. We hope that this review can urgently consolidate and disseminate information to aid researchers in designing and implementing optimized COVID-19 testing protocols to increase the availability, accuracy, and speed of widespread COVID-19 testing.

Rapid COVID-19 vaccine development

The day after COVID-19

Assessing the severity of COVID-19.

The Promise and Peril of Antibody Testing for COVID-19.

Strategies to trace back the origin of COVID-19

Covid-19 mass testing facilities could end the epidemic rapidly.

The COVID-19 challenge

At the heart of COVID-19

Overcoming the bottleneck to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection.

The current COVID-19 pandemic presents a serious public health crisis, and a better understanding of the scope and spread of the virus would be aided by more widespread testing. Nucleic-acid based tests currently offer the most sensitive and early detection of COVID-19. However, the "gold standard" test pioneered by the United States Center for Disease Control & Prevention, takes several hours to complete and requires extensive human labor, materials such as RNA extraction kits that could become in short supply and relatively scarce qPCR machines. It is clear that a huge effort needs to be made to scale up current COVID-19 testing by orders of magnitude. There is thus a pressing need to evaluate alternative protocols, reagents, and approaches to allow nucleic-acid testing to continue in the face of these potential shortages. There has been a tremendous explosion in the number of papers written within the first weeks of the pandemic evaluating potential advances, comparable reagents, and alternatives to the "gold-standard" CDC RT-PCR test. Here we present a collection of these recent advances in COVID-19 nucleic acid testing, including both peer-reviewed and preprint articles. Due to the rapid developments during this crisis, we have included as many publications as possible, but many of the cited sources have not yet been peer-reviewed, so we urge researchers to further validate results in their own labs. We hope that this review can urgently consolidate and disseminate information to aid researchers in designing and implementing optimized COVID-19 testing protocols to increase the availability, accuracy, and speed of widespread COVID-19 testing.

New Zealand eliminates COVID-19

The COVID-19 Curriculum.

Emergent Strategies for the Next Phase of COVID-19

Steps towards COVID-19 suppression

An alternative COVID-19 checklist

COVID-19 and programmatic assessment

Countries test tactics in 'war' against COVID-19.

Avoiding Disinformation Traps in COVID-19

The impact of COVID-19.

COVID-19 spurs wave of innovative diagnostics.

Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2

OBJECTIVES: We aimed to evaluate the role of rapid serological tests in the management of coronavirus disease 2019 (COVID-19) patients. METHODS: This retrospective study enrolled 16 real-time reverse transcription polymerase chain reaction-confirmed symptomatic patients with COVID-19 and 58 COVID-19 negative patients at a medical center in Taiwan over a 3-month period. Serial serum samples were collected and tested for antibody response using four point-of-care (POC) lateral flow immunoassays (LFIA) (ALLTEST 2019-nCoV IgG/IgM Rapid Test, Dynamiker 2019-nCoV IgG/IgM Rapid Test, ASK COVID-19 IgG/IgM Rapid Test, and Wondfo SARS-CoV-2 Antibody Test). Time-dependent detection sensitivity and timeliness of seroconversion were determined and compared between the four POC rapid tests. RESULTS: The overall sensitivity and specificity of the four tests for detecting anti-SARS-CoV-2 antibodies after 3 weeks of symptom onset were 100% and 100%, respectively. There was no significant difference between the rapid tests used for detection of IgM and IgG separately and those used for detection of combined total antibody (mainly IgM/IgG). There was no significant difference between the four POC rapid tests in terms of time required for determining seroconversion of COVID-19. Patients with COVID-19 with pneumonia demonstrated shorter seroconversion time than those without pneumonia. CONCLUSION: Though the POC antibody rapid tests based on LFIA showed reliable performance in the detection of SARS-CoV-2-specific antibodies, the results of these tests should be interpreted and applied appropriately in the context of antibody dynamic of COVID-19 infection. COVID-19 patients complicated with pneumonia exhibited earlier anti-SARS-CoV-2 antibody response than COVID-19 patients without pneumonia.